pixuvri

Small moleculeexperimental

Pixantrone is an experimental antineoplastic (anti-cancer) drug, an analogue of mitoxantrone with fewer toxic effects on cardiac tissue. It acts as a topoisomerase II poison and intercalating agent. The code name BBR 2778 refers to pixantrone dimaleate, the actual substance commonly used in clinical trials. — Wikipedia

Clinical trial activity

17 trials · 16 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
13
Phase 3
5
Phase 4
0

Earliest trial started Dec 1, 2001 (NCT00060684)

Timeline

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • DNACROSS-LINKING AGENT

    DNA cross-linking agent

    Forms formaldehyde-mediated adducts with DNA (favours the CpG motif) and stimulates topoisomerase II-mediated DNA cleavage

    Binds d(TCATATGA)2, d(CCGAGAATTCCGG)2 {double bulge}, d(TACGATGAGTA) : d(TACCATCGTA) {single bulge}

Chemistry & pharmacology

Loading structure…

SMILES

NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O
Mol. weight
325.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5,8-bis((2-aminoethyl)amino)-2-aza-anthracene-9,10-dione
  • 5,8-bis(2-aminoethylamino)-2-azaanthracene-9,10-dione
  • 6,9-aea-biqdo
  • 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
  • 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
  • 6,9-bis((2-aminoethyl)amino)benzo(g)isoquinoline-5,10-dione
  • bbr2778
  • bbr 2778
  • bbr-2778
  • bbr-2778
  • bbr-2778
  • pix
  • pix
  • pixantrone
  • pixantrone
  • pixantrone
  • pixantrone
  • pixantrone
  • pixantrone
  • pixantrone
  • pixantrone dimaleate
  • pixantrone dimaleate
  • pixantrone dimaleate
  • pixantrone dimaleate
  • pixantrone dimaleate
  • pixantrone dimaleate
  • pixantrone maleate
  • pixantrone maleate
  • pixuvri
  • pixuvri

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03458260Phase 2Mar 26, 2018The Lymphoma Academic Research Organisation, University of London, University of Paris, University of Strasbourg
NCT02800889Phase 1Oct 1, 2016CTI BioPharma, University of Southern California
NCT02678299Phase 1/Phase 2 (Phase 2)Feb 1, 2016Aarhus University
NCT02499003Phase 2Aug 1, 2015CTI BioPharma, Johannes Gutenburg University, Roche
NCT01632436Phase 1May 1, 2012CTI BioPharma, University of Texas, San Antonio
NCT01491841Phase 1/Phase 2 (Phase 2)Nov 1, 2011CTI BioPharma, Duke University
NCT01321541Phase 3Apr 1, 2011CTI BioPharma
NCT01086605Phase 2May 1, 2010Mayo Clinic, National Cancer Institute (NCI)
NCT00577161Phase 3Sep 1, 2007CTI BioPharma
NCT00551239Phase 3Aug 1, 2007CTI BioPharma
NCT00268853Phase 2Nov 1, 2005CTI BioPharma
NCT00106600Phase 1/Phase 2 (Phase 2)Mar 1, 2005CTI BioPharma
NCT00060671Phase 3Jan 1, 2005CTI BioPharma
NCT00088530Phase 3Jul 1, 2004CTI BioPharma
NCT00069966Phase 2Apr 1, 2003Theradex, University of Nebraska
NCT00053105Phase 1Feb 1, 2002Theradex, University of Texas at Houston
NCT00060684Phase 1Dec 1, 2001CTI BioPharma
Showing 17 of 17 trials
Page 1 / 1

Organizations

Research & Development (16)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CTI BioPharmaFor profit121032001
TheradexFor profit2222002
Aarhus UniversityAcademic/Hospital1112016
Duke UniversityAcademic/Hospital1112011
Johannes Gutenburg UniversityAcademic/Hospital1112015
Mayo ClinicAcademic/Hospital1012010
National Cancer Institute (NCI)Government1112010
RocheFor profit1012015
The Lymphoma Academic Research OrganisationAcademic/Hospital1112018
University of LondonAcademic/Hospital1012018
University of NebraskaAcademic/Hospital1012003
University of ParisAcademic/Hospital1012018
University of Southern CaliforniaAcademic/Hospital1012016
University of StrasbourgAcademic/Hospital1012018
University of Texas at HoustonAcademic/Hospital1012002
University of Texas, San AntonioAcademic/Hospital1012012
16 organizations
Page 1 / 1